Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of BI 3814916 in Healthy Subjects
NCT07486115Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 3814916 (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse events (AEs) assessed as drug-related by the investigator up to 111 days. Started May 2026; status: recruiting.
02
Drugs
BI 3814916
Beyond the preview
Go deeper on NCT07486115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486115.